
    
      This is a special drug use surveillance on long-term use of Voglibose (Basen) designed to
      determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent
      progression to type 2 diabetes mellitus in participants with impaired glucose tolerance in
      the routine clinical setting.

      Particioants will be patients with impaired glucose tolerance. The planned sample size is
      1,000.

      The usual adult dosage is 0.2 mg of voglibose administered orally three times daily
      immediately before each meal.
    
  